Ishara Investments LP Makes New $1.78 Million Investment in Zentalis Pharmaceuticals, Inc. $ZNTL

Ishara Investments LP purchased a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,320,000 shares of the company’s stock, valued at approximately $1,782,000. Zentalis Pharmaceuticals accounts for 2.1% of Ishara Investments LP’s investment portfolio, making the stock its 17th biggest position. Ishara Investments LP owned approximately 1.83% of Zentalis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Sivia Capital Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth approximately $27,000. Qube Research & Technologies Ltd purchased a new position in shares of Zentalis Pharmaceuticals in the second quarter worth $37,000. Voleon Capital Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth $41,000. Algert Global LLC purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth $73,000. Finally, Barr E S & Co. lifted its holdings in shares of Zentalis Pharmaceuticals by 43.8% in the fourth quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock worth $78,000 after buying an additional 17,500 shares in the last quarter.

Analyst Ratings Changes

Several research firms have recently commented on ZNTL. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 target price on the stock. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, May 31st. Guggenheim boosted their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Tuesday, April 7th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.83.

Zentalis Pharmaceuticals Stock Up 2.8%

Zentalis Pharmaceuticals stock opened at $3.62 on Thursday. The company has a market cap of $257.71 million, a price-to-earnings ratio of -2.09 and a beta of 1.96. The firm’s fifty day moving average is $4.07 and its 200 day moving average is $2.90. Zentalis Pharmaceuticals, Inc. has a 52-week low of $1.13 and a 52-week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). On average, equities research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -1.92 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.